Nurse Anesthetist - CR in Platte, SD Accepting Medicare
1 Nurse Anesthetist - CR nurses found. Showing 1 - 1
 Jared Jay Veurink, CRNA Nurse Anesthetist, Certified Registered Medicare: Not Enrolled in Medicare Practice Location: 601 E 7th St, #1, Platte, SD 57369 Phone: 605-337-3364 |
News Archive
Emerson Resources announces partnership with Bio Research
Emerson Resources, Inc., a premier pharmaceutical solutions company, today announced that it has formed a strategic partnership with Bio Research, a contract research organization that specializes in the agrichemical and related industries, to further extend its business development capabilities. The exclusive partnership leverages the expertise of industry veteran Robert Westbrook, CEO of Bio Research, who is spearheading Emerson Resources' intensified business development and sales efforts.
Dems move forward with 'deem and pass' strategy; Some Dem. holdouts express support for reform
The Hill's Blog Briefing Room: "The House will have a clean up-or-down vote on the Senate's healthcare vote in the form of a rules vote, Majority Leader Steny Hoyer (D-Md.) said Wednesday. As Democrats prepare to move forward with health reform efforts, Hoyer seemed to confirm the so-called 'deem and pass' strategy that would see the House indirectly approve the Senate's health bill through a vote on a rule making changes to it.
Cells lose ability to defend against transposons as they age
Even in our DNA there is no refuge from rogues that prey on the elderly. Parasitic strands of genetic material called transposable elements - transposons - lurk in our chromosomes, poised to wreak genomic havoc. Cells have evolved ways to defend themselves, but in a new study, Brown University researchers describe how cells lose this ability as they age, possibly resulting in a decline in their function and health.
Dynavax Technologies to present data on its SD-101 Phase 1b trial for chronic HCV infection
Dynavax Technologies Corporation announced today data from two studies that differentiate SD-101 from standard-of-care as well as emerging treatments for chronic HCV infection. The findings of a Phase 1b clinical trial and an in vitro study of SD-101's mechanism of action show that the second-generation TLR9 agonist is well tolerated and safe and induces both IFN-lambda and IFN-alpha at concentrations producing antiviral activity. The data will be presented at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria in April 2010.
› Verified 3 days ago